Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Cholesterol

Experimental cholesterol drug failed to prevent cardiovascular events

Phase III trial halted early as treatment did not reduce rate of vascular events in patients with high-risk disease.

3D render of the cholesterol ester transfer protein inhibitor, evacetrapib

Source: Shutterstock.com

In a phase III trial, researchers assessed the effect of cholesterol ester transfer protein inhibitor, evacetrapib, on cardiovascular outcomes in 12,092 patients with high-risk cardiovascular disease.

In phase II trials, the cholesterol ester transfer protein inhibitor, evacetrapib, increased high-density lipoprotein (HDL) cholesterol levels by up to 130% and reduced low-density lipoprotein (LDL) cholesterol by up to 35%, but it was unknown if this translated to an effect on cardiovascular outcomes.

In a phase III trial, 12,092 patients with high-risk cardiovascular disease were randomly assigned to 130mg dose of evacetrapib or placebo for two years.

The trial was stopped after a median follow-up of 28 months owing to futility. At this point, the primary endpoint (death from cardiovascular causes, myocardial infarction, stroke, coronary revascularisation, or hospitalisation for unstable angina) had occurred in 12.9% of the evacetrapib group and 12.8% of the placebo group (hazard ratio 1.01; 95% confidence interval 0.91–1.11; P=0.91).

Reporting in The New England Journal of Medicine[1] (online, 18 May 2017), the researchers say the results reinforce the need for adequately powered clinical trials of new agents, even when results have been seen with surrogate endpoints.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2017.20203054

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Sport and Exercise Medicine for Pharmacists

    Sport and Exercise Medicine for Pharmacists

    All the information you need to provide patients with evidence-based advice on sports and exercise related health matters.

    £27.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • English Delftware Drug Jars

    English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.

    £54.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • 3D render of the cholesterol ester transfer protein inhibitor, evacetrapib

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.